In clinical trials for MS, there were no treatment-related deaths or increased risk of cancer; side effects that occurred more frequently with<unk>  versus interferon included infections (65% versus 57%), skin rashes (37% versus 19%) and liver complications (approximately 18% versus 12%).
Daclizumab
Tocilizumab
Brolucizumab
Satralizumab
Ravulizumab
Reslizumab
Natalizumab
Benralizumab